An innovative approach to address unmet medical need in cancer therapy

Lead development candidate CB-103 is a small molecule that has been selected as drug development candidate for preclinical and clinical development as targeted oncology therapy.

cellestia-biotech-hero

An innovative approach to address unmet medical need in cancer therapy

Lead development candidate CB-103 is a small molecule that has been selected as drug development candidate for preclinical and clinical development as targeted oncology therapy.

Intellectual Property

Cellestia Biotech holds a worldwide exclusive license on the intellectual property rights (IPR) for CB-103 and related series of analogues, for development and commercialization. The patent was recently granted in the USA and Singapore, with additional countries following, representing key milestones in securing IPR for Cellestia. Considering that CB-103 is targeting a number of orphan (rare) oncology and / or pediatric indications, it is not unlikely to expect patent life extensions to be granted. Additional patent protection is currently under review for manufacturing, next generation compounds and the biomarker development to establish a companion diagnostic for the selection of patients to be treated with CB-103.